HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $87 Price Target
HC Wainwright & Co. analyst Douglas Tsao reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $87 price target.
Reported Late Wednesday Feb 22, Apellis Pharmaceuticals Announces Pricing Of $350M Public Offering Of 3,174,603 Shares Of Common Stock At A Price Of $63/Share And Pre-Funded Warrants To Purchase 2,380,956 Shares Of Common Stock At A Price Of $62.99/Sha…
Apellis Pharmaceuticals, Inc., (NASDAQ:APLS), a global biopharmaceutical company and leader in complement, today announced the pricing of its underwritten public offering of 3,174,603 shares of its common
Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $139
Raymond James analyst Steven Seedhouse maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Strong Buy and raises the price target from $123 to $139.
Needham Maintains Buy on Apellis Pharmaceuticals, Maintains $80 Price Target
Needham analyst Joseph Stringer maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and maintains $80 price target.
Apellis Pharmaceuticals Q4 EPS $(1.50) Beats $(1.57) Estimate
Apellis Pharmaceuticals (NASDAQ:APLS) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.57) by 4.46 percent. This is a 6.83 percent increase over losses of $(1.61) per share
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Gainers
Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Why Are Apellis Pharmaceuticals Shares Trading Higher Today?
The FDA approved Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) Syfovre (pegcetacoplan injection) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre…
Stifel Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $75
Stifel analyst Annabel Samimy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $65 to $75.
Baird Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $105
Baird analyst Colleen Kusy maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Outperform and raises the price target from $90 to $105.
Needham Reiterates Buy on Apellis Pharmaceuticals, Raises Price Target to $80
Needham analyst Joseph Stringer reiterates Apellis Pharmaceuticals (NASDAQ:APLS) with a Buy and raises the price target from $70 to $80.